Torrent Pharmaceuticals today announced the launch of its semaglutide brands – Symbolic and Semalix – in both oral and injectable forms in India. With this launch, the company has expanded its presence in the field of metabolic disorders like Type-2 diabetes and obesity.
Commenting on the launch, Amal Kelshikar, CEO – India Business, Torrent Pharmasaid, “Metabolic disorders are one of the most significant health challenges in India, where a large portion of our population is affected by Type-2 diabetes. Our entry into the GLP-1 therapy segment reflects Torrent’s commitment towards expanding treatment options at affordable rates for healthcare professionals managing complex metabolic conditions. We are proud to be the first Indian company to make this treatment available in both oral and injectable forms, providing healthcare professionals “Patients get a holistic option for treatment.”
GLP-1 (glucagon-like peptide-1) receptor agonists are established prescription medications for the management of type 2 diabetes and obesity. They help by increasing insulin secretion, reducing glucagon levels and controlling appetite. They have been proven to be effective in lowering hemoglobin A1c (HbA1c), promoting weight loss, and reducing the risk of cardiovascular events by mimicking the GLP-1 hormone.
Comments are closed.